Clarithromycin use and risk of death in patients with ischemic heart disease

Søren Skøtt Andersen; Morten Lock Hansen; Mette Lykke Norgaard; Fredrik Folke; Emil Loldrup Fosbøl; Steen Z Abildstrøm; Jakob Raunsø; Mette Madsen; Lars Køber; Gunnar H Gislason; Christian Torp-Pedersen; Søren Skøtt Andersen; Morten Lock Hansen; Mette Lykke Norgaard; Fredrik Folke; Emil Loldrup Fosbøl; Steen Z Abildstrøm; Jakob Raunsø; Mette Madsen; Lars Køber; Gunnar H Gislason; Christian Torp-Pedersen

doi:10.1159/000315394

Clarithromycin use and risk of death in patients with ischemic heart disease

Søren Skøtt Andersen, Morten Lock Hansen, Mette Lykke Norgaard, Fredrik Folke, Emil Loldrup Fosbøl, Steen Z Abildstrøm, Jakob Raunsø, Mette Madsen, Lars Køber, Gunnar H Gislason, Christian Torp-Pedersen, Søren Skøtt Andersen, Morten Lock Hansen, Mette Lykke Norgaard, Fredrik Folke, Emil Loldrup Fosbøl, Steen Z Abildstrøm, Jakob Raunsø, Mette Madsen, Lars KøberGunnar H Gislason, Christian Torp-Pedersen

15 Citations (Scopus)

Abstract

Objectives: To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD). Methods: Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality. Results: The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years. Conclusions: The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.

Original language	English
Journal	Cardiology
Volume	116
Issue number	2
Pages (from-to)	89-97
Number of pages	9
ISSN	0008-6312
DOIs	https://doi.org/10.1159/000315394
Publication status	Published - 1 Jul 2010

Access to Document

10.1159/000315394

Cite this

Andersen, S. S., Hansen, M. L., Norgaard, M. L., Folke, F., Fosbøl, E. L., Abildstrøm, S. Z., Raunsø, J., Madsen, M., Køber, L., Gislason, G. H., Torp-Pedersen, C., Andersen, S. S., Hansen, M. L., Norgaard, M. L., Folke, F., Fosbøl, E. L., Abildstrøm, S. Z., Raunsø, J., Madsen, M., ... Torp-Pedersen, C. (2010). Clarithromycin use and risk of death in patients with ischemic heart disease. Cardiology, 116(2), 89-97. https://doi.org/10.1159/000315394

Andersen, SS, Hansen, ML, Norgaard, ML, Folke, F, Fosbøl, EL, Abildstrøm, SZ, Raunsø, J, Madsen, M , Køber, L, Gislason, GH, Torp-Pedersen, C, Andersen, SS, Hansen, ML, Norgaard, ML, Folke, F, Fosbøl, EL, Abildstrøm, SZ, Raunsø, J, Madsen, M, Køber, L , Gislason, GH & Torp-Pedersen, C 2010, 'Clarithromycin use and risk of death in patients with ischemic heart disease', Cardiology, vol. 116, no. 2, pp. 89-97. https://doi.org/10.1159/000315394

@article{1ca4a2007d3e11df928f000ea68e967b,

title = "Clarithromycin use and risk of death in patients with ischemic heart disease",

abstract = "Objectives: To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD). Methods: Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality. Results: The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years. Conclusions: The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.",

author = "Andersen, {S{\o}ren Sk{\o}tt} and Hansen, {Morten Lock} and Norgaard, {Mette Lykke} and Fredrik Folke and Fosb{\o}l, {Emil Loldrup} and Abildstr{\o}m, {Steen Z} and Jakob Rauns{\o} and Mette Madsen and Lars K{\o}ber and Gislason, {Gunnar H} and Christian Torp-Pedersen and Andersen, {S{\o}ren Sk{\o}tt} and Hansen, {Morten Lock} and Norgaard, {Mette Lykke} and Fredrik Folke and Fosb{\o}l, {Emil Loldrup} and Abildstr{\o}m, {Steen Z} and Jakob Rauns{\o} and Mette Madsen and Lars K{\o}ber and Gislason, {Gunnar H} and Christian Torp-Pedersen",

note = "Copyright {\textcopyright} 2010 S. Karger AG, Basel.",

year = "2010",

month = jul,

day = "1",

doi = "10.1159/000315394",

language = "English",

volume = "116",

pages = "89--97",

journal = "Cardiology",

issn = "0008-6312",

publisher = "S Karger AG",

number = "2",

}

TY - JOUR

T1 - Clarithromycin use and risk of death in patients with ischemic heart disease

AU - Andersen, Søren Skøtt

AU - Hansen, Morten Lock

AU - Norgaard, Mette Lykke

AU - Folke, Fredrik

AU - Fosbøl, Emil Loldrup

AU - Abildstrøm, Steen Z

AU - Raunsø, Jakob

AU - Madsen, Mette

AU - Køber, Lars

AU - Gislason, Gunnar H

AU - Torp-Pedersen, Christian

AU - Andersen, Søren Skøtt

AU - Hansen, Morten Lock

AU - Norgaard, Mette Lykke

AU - Folke, Fredrik

AU - Fosbøl, Emil Loldrup

AU - Abildstrøm, Steen Z

AU - Raunsø, Jakob

AU - Madsen, Mette

AU - Køber, Lars

AU - Gislason, Gunnar H

AU - Torp-Pedersen, Christian

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Objectives: To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD). Methods: Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality. Results: The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years. Conclusions: The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.

AB - Objectives: To examine whether treatment with clarithromycin was associated with an increased risk of death in patients with preexisting ischemic heart disease (IHD). Methods: Employing nationwide registers, all patients with IHD events from 1997 to 2007 who subsequently claimed prescriptions for dual antibiotic treatment for eradication treatment were identified. The primary endpoint was all-cause mortality. Results: The study included 214,330 individuals with IHD; 5,265 (2.5 %) of these claimed prescriptions for dual antibiotics. Compared with IHD patients not undergoing eradication therapy, no increase in the risk of all-cause mortality was demonstrated (HR 1.02; 95% CI 0.84-1.23, p = 0.87) after 5 years. Conclusions: The use of clarithromycin in the setting of eradication treatment for Helicobacter pylori in patients with IHD was not associated with an increased risk of death.

U2 - 10.1159/000315394

DO - 10.1159/000315394

M3 - Journal article

SN - 0008-6312

VL - 116

SP - 89

EP - 97

JO - Cardiology

JF - Cardiology

IS - 2

ER -

Clarithromycin use and risk of death in patients with ischemic heart disease

Abstract

Access to Document

Fingerprint

Cite this